



## ASX ANNOUNCEMENT

### Lumos Diagnostics Announces A\$10.0 million Equity Raising and Welcomes Tenmile Ventures as a New Shareholder

**MELBOURNE, Australia (4 September 2024)** – Lumos Diagnostics Holdings Limited (**LDX** or the **Company**) is pleased to announce that it has launched an equity raising through a pro rata accelerated non-renounceable entitlement offer (**Entitlement Offer**).

#### Key highlights

- The Entitlement Offer will comprise an accelerated non-renounceable pro rata entitlement offer to eligible LDX shareholders to raise up to approximately A\$10.0 million (before costs). The retail component of the Entitlement Offer is underwritten up to approximately A\$6.0 million.
- Funds raised under the Entitlement Offer will be applied towards completion of the FebriDx Clinical Laboratory Improvement Amendment (CLIA) waiver trial in the US, product development, sales and marketing activities and general working capital (and costs of the offer).
- Tenmile Ventures Pty Ltd (a wholly owned subsidiary of Tattarang) have acquired 45.0 million shares, which represents a 9.3% shareholding in LDX. Tenmile intend to subscribe in full for their entitlement and are acting as a sub-underwriter to the Entitlement Offer. It is anticipated that following completion of the entitlement offer, Tenmile will become the largest shareholder of LDX.
- Ryder Capital Limited, an existing long-term shareholder, also intend to subscribe in full for their entitlement and are acting as a sub-underwriter to the Entitlement Offer.
- Bell Potter Securities Limited is acting as lead manager and underwriter of the Entitlement Offer.

#### The Entitlement Offer

The Entitlement Offer which seeks to raise approximately A\$10.0 million (before costs) will consist of a 1-for-1.82 accelerated pro-rata non renounceable entitlement offer, including:

- an institutional entitlement offer to raise approximately A\$4.0 million (before costs) (**Institutional Entitlement Offer**); and
- a retail entitlement offer to raise approximately A\$6.0 million (before costs) (**Retail Entitlement Offer**). The Retail Entitlement Offer is underwritten up to approximately A\$6.0 million.

Under the Entitlement Offer, eligible shareholders are invited to subscribe for 1 new fully paid ordinary share in the capital of the Company (**New Share**) for every 1.82 Company Shares (**Shares**) held as at 7:00pm (Sydney, Australia time) on Friday, 6 September 2024 (**Record Date**). Fractional entitlements will be rounded down to the nearest whole Share. All New Shares in the Entitlement Offer will be issued at a price of A\$0.038 (3.8 cents) per New Share (**Offer Price**) which represents:

- a 17.4% discount to the last close price of A\$0.046 on Tuesday, 3 September 2024; and
- a 12.0% discount to the Company's 5-day VWAP of A\$0.0432 up to and including Tuesday, 3 September 2024.



Entitlements cannot be traded on the ASX or transferred. Eligible shareholders who do not take up their entitlements under the Entitlement Offer in full or in part, will not receive any value in respect to those entitlements not taken up.

The Company's Shares will remain in a trading halt until the commencement of trading on Friday, 6 September 2024 pending completion of the Institutional Entitlement Offer.

### **Underwriting**

Bell Potter Securities Limited (**Bell Potter**) are acting as lead manager to the Entitlement Offer. The Retail Entitlement Offer is underwritten by Bell Potter up to approximately A\$6.0 million, pursuant to an underwriting agreement between the Company and Bell Potter dated 4 September 2024 (**Underwriting Agreement**).

Tenmile Ventures and Ryder Capital will be acting as sub-underwriters to the retail entitlement offer for up to approximately A\$6.0 million. In addition, they have committed to take up their full entitlements of A\$1.5 million, which in total is up to approximately A\$7.5 million commitment in aggregate.

Further details with respect to the Underwriting Agreement are set out in the investor presentation in respect of the Entitlement Offer which the Company will release to ASX contemporaneously with this announcement.

### **Institutional Entitlement Offer**

Eligible institutional shareholders will be invited to participate in the Institutional Entitlement Offer, which is being conducted today, Wednesday, 4 September 2024 and tomorrow Thursday, 5 September 2024. Eligible institutional shareholders can choose to take up all, part or none of their entitlements under the Entitlement Offer.

Entitlements not taken up by institutional shareholders cannot be traded on market or transferred. Entitlements not taken up by eligible institutional shareholders, and institutional entitlements that would otherwise have been offered to ineligible institutional shareholders (if any), will be offered to eligible institutional shareholders at the Offer Price.

### **Retail Entitlement Offer**

Eligible retail shareholders with a registered address in Australia or New Zealand will be invited to participate in the Retail Entitlement Offer. The Retail Entitlement Offer will open on Wednesday, 11 September 2024 and closes at 5:00pm (Sydney, Australia time) on Wednesday, 2 October 2024 (**Retail Offer Period**), unless otherwise extended by the Company in accordance with the ASX Listing Rules.

Further details about the Retail Entitlement Offer will be set out in the retail offer booklet, which the Company expects to lodge with the ASX on Wednesday, 11 September 2024 (**Retail Offer Booklet**).

It is currently envisaged that eligible retail shareholders who have applied for their full Entitlement will be able to apply for additional Shares under a top-up offer, subject to applications being received by the closing date (**Top Up Offer**).

The Entitlement Offer and Top-Up Offer will provide eligible shareholders with the opportunity to take up new Shares proportional to their shareholding and mitigate the effect of dilution. Eligible shareholders who do not take up their entitlement under the Entitlement Offer in full or in part, will not



receive any value in respect to those entitlements not taken up.

#### **Use of proceeds received under the Entitlement Offer**

The funds raised under the Entitlement Offer (after deduction of the costs associated with the Entitlement Offer) are expected to be used to fund completion of the FebriDx CLIA waiver trial in the US, product development, sales and marketing activities and general working capital.

#### **Tenmile Ventures**

Lumos is pleased to welcome dedicated health technology investment business Tenmile Ventures Pty Ltd (**Tenmile**) (owned by Tattarang Pty Ltd (**Tattarang**), one of Australia's largest private investment groups) to its register following its block trade with Planet Innovation Holdings Limited (**Planet Innovation**).

On settlement of the block trade, Tenmile will hold 45.0 million fully paid ordinary shares in the capital of the Company (being 9.3% of the Company's issued capital) and Planet Innovation's shareholding will be reduced from 68.0 million to 23.0 million shares (being 4.8% of the Company's issued capital, prior to the issue of New Shares under the Entitlement Offer).

Commenting on the block trade, Lumos CEO & Managing Director, Doug Ward stated:

"We are honored to welcome an investor of Tenmile's calibre to Lumos. We are strongly aligned in our vision to address unmet needs in human health and look forward to working together to do this, while driving the growth of our business. We also thank Ryder Capital, a longstanding and highly engaged shareholder, for their ongoing support.

In parallel, I would like to extend gratitude to Planet Innovation for their long-term support of Lumos. We look forward to continuing our important relationship with Planet Innovation as a key supplier and long-term shareholder.

The funding under this Entitlement Offer will underpin our efforts to complete the CLIA waiver study for our FebriDx point of care diagnostic test in the US. Achieving CLIA waiver status for FebriDx is expected to enable label extension in the US - from the current, moderate-complex label - to include CLIA waived settings. This would greatly expand our market opportunity for FebriDx in the US from around 18,000 sites to approximately 270,000 sites. Recognizing the important role FebriDx can play in reducing antibiotic overprescription, we are aiming to complete the CLIA waiver study ahead of the 2025 US flu season."

Please refer to the substantial shareholder notices lodged by Tenmile and Planet Innovation for further details.

Tenmile is a dedicated health technology investment business focused on supporting and building early-stage companies through all stages of growth. Tenmile has team members in Perth and Sydney and seeks to address unmet needs in human health and support the development of a globally significant health science and technology sector in Australia. Further details in respect of Tenmile are available from its website located at: [www.tenmile.com](http://www.tenmile.com).

Tattarang is the private investment group of Andrew and Nicola Forrest. It is proudly Australian and invests across a wide variety of sectors and asset classes, including in real assets, public and private markets and is the owner of Tenmile. Further details in respect of Tattarang are available from its



website located at: [www.tattarang.com](http://www.tattarang.com).

### Offer Timetable

Activity	Date
Announcement of the Entitlement Offer	Wednesday, 4 September 2024
Institutional Entitlement Offer launch	Prior to 12.00pm (AEST) on Wednesday, 4 September 2024
Results of Institutional Entitlement Offer announced and Trading Halt lifted	Friday, 6 September 2024
Record Date for eligibility under the Entitlement Offer	7.00pm (AEST) on Friday, 6 September 2024
Retail Offer Booklet lodged with the ASX	Wednesday, 11 September 2024
Retail Entitlement Offer opens	Wednesday, 11 September 2024
Settlement of New Shares issued under the Institutional Entitlement Offer	Wednesday, 11 September 2024
Allotment of New Shares under the Institutional Entitlement Offer	Thursday, 12 September 2024
New Shares issued under the Institutional Entitlement Offer commence trading on ASX	Friday, 13 September 2024
Last day to extend Retail Entitlement Offer	Before 12.00pm (AEST) on 27 September 2024
Closing Date of Retail Entitlement Offer	Wednesday, 2 October 2024
Results of Retail Entitlement Offer announced	Tuesday, 8 October 2024
Settlement of New Shares issued under the Retail Entitlement Offer	Wednesday, 9 October 2024
Allotment of New Shares issued under the Retail Entitlement Offer	Before 12.00pm (AEST) on Wednesday, 9 October 2024
New Shares issued under the Retail Entitlement Offer commence trading on ASX	Thursday, 10 October 2024



*The timetable above (and each reference to or to dates in this Retail Offer Booklet) is indicative only. The Company, in consultation with the Lead Manager, reserves the right to amend any or all of these dates and times without notice, subject to the Corporations Act, the Listing Rules and other applicable laws. Any extension of the Closing Date will have a consequential effect on the allotment date of New Shares. The commencement of quotation of the New Shares is subject to confirmation from ASX.*

*The Company also reserves the right not to proceed with the Retail Entitlement Offer in whole or in part at any time prior to allotment and issue of the New Shares. In that event, the relevant Application Monies (without interest) will be returned in full to Applicants. Cooling-off rights do not apply to an investment in New Shares. You cannot withdraw your Application. Eligible Retail Shareholders wishing to participate in the Retail Entitlement Offer are encouraged to submit their Entitlement and Acceptance Form as soon as possible after the Retail Entitlement Offer opens.*

If you have any doubt about whether you should participate in the Retail Entitlement Offer, you should seek professional financial advice from your stockbroker, solicitor, accountant or other suitably qualified professional financial adviser before making any investment decision. For further information on the Entitlement Offer, if you have questions on how to complete the Entitlement and Acceptance Form, or have lost your Entitlement and Acceptance Form and would like a replacement form, you may contact the Lumos Diagnostics Company Secretary on +61 3 9087 1598 between 9:00am and 5:00pm (AEST) during Monday to Friday, or by e-mail [cosec@lumosdiagnostics.com](mailto:cosec@lumosdiagnostics.com).

#### **Additional information**

Additional information in relation to the Entitlement Offer and the Company can be found in the investor presentation released to the ASX simultaneously with this announcement, which contains important information, including a breakdown of sources and uses of funds, key risks and foreign selling restrictions with respect to the Entitlement Offer as well as a summary of the underwriting agreement in connection with the Entitlement Offer.

Nothing contained in this announcement constitutes investment, legal, tax or other advice. Investors should seek appropriate professional advice before making any investment decision. All amounts are in Australian dollars unless otherwise indicated.

An Appendix 3B for the proposed issue of New Shares will be released in conjunction with this announcement. Further details on the fees payable to Bell Potter are set out in the Appendix 3B.

**This announcement is authorised for release by the Lumos Board of Directors.**

**– ENDS –**



## About Lumos Diagnostics

*Lumos Diagnostics specialises in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customised assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercialises novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.*

*For more information visit [lumosdiagnostics.com](http://lumosdiagnostics.com).*

## Forward-Looking Statements

*This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.*

## Media Contacts:

Haley Chartres – Australia

HACK Director

[haley@hck.digital](mailto:haley@hck.digital)

+61 423 139 163

## Investor Contact:

Jane Lowe

Managing Director, IR Department

[ir@lumosdiagnostics.com](mailto:ir@lumosdiagnostics.com)

+61 411 117 774

## Company Registered Office:

Lumos Diagnostics Holdings Ltd

Level 4, 100 Albert Rd

South Melbourne, VIC 3205

[info@lumosdiagnostics.com](mailto:info@lumosdiagnostics.com)

+61 3 9087 1598

## Important Notices

This announcement is issued by Lumos Diagnostics Holdings Limited. This announcement is not a prospectus or offering document under Australian law or under any other law. It is for information purposes only and does not constitute an offer, invitation, solicitation, advice or recommendation to subscribe for, retain or purchase any entitlements or securities in Lumos Diagnostics Holdings Limited in any jurisdiction. This letter does not constitute financial product advice and does not and will not form any part of any contract for the acquisition of Lumos Diagnostics Holdings Limited ordinary shares.